Quetiapine Monotherapy in adolescents with bipolar disorder Comorbid with conduct disorder

Gabriele Masi, Simone Pisano, Chiara Pfanner, Annarita Milone, Azzurra Manfredi

Research output: Contribution to journalArticlepeer-review

Abstract

Bipolar Disorders (BD) are often comorbid with disruptive behaviour disorders (DBDs) (oppositional-defiant disorder or conduct disorder), with negative implications on treatment strategy and outcome. The aim of this study was to assess the efficacy of quetiapine monotherapy in adolescents with BD comorbid with conduct disorder (CD). A consecutive series of 40 adolescents (24 males and 16 females, age range 12-18 years, mean age 14.9±2.0 years), diagnosed with a clinical interview (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children - Present and Lifetime Version [K-SADS-PL]) according to American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria were included. All the patients were treated with quetiapine monotherapy (mean final dose 258±124 mg/day, range 100-600 mg/day). At the end-point (3 months), 22 patients (55.0%) were responders (Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2 and CGI-Severity [CGI-S]≤3 and improvement of at least 30% Children's Global Assessment Scale [C-GAS] during 3 consecutive months). Both CGI-S and C-GAS significantly improved (p50% of the patients.

Original languageEnglish
Pages (from-to)568-571
Number of pages4
JournalJournal of Child and Adolescent Psychopharmacology
Volume23
Issue number8
DOIs
Publication statusPublished - Oct 1 2013

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Quetiapine Monotherapy in adolescents with bipolar disorder Comorbid with conduct disorder'. Together they form a unique fingerprint.

Cite this